Buscar
Adagene Inc
ADAGAñadir a la lista de seguimiento
4.470USD
-0.310-6.49%
Cierre 07/02, 13:00（ET）Cotizaciones retrasadas 15 min
211.81MCap. mercado
PérdidaP/E TTM
Más Datos de Adagene Inc Compañía
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. The Company is principally engaged in the research, development and production of monoclonal antibody drugs for cancers. The Company’s main products include: ADG106 is being developed for the treatment of advanced solid tumors and non-Hodgkin's lymphoma, or NHL. ADG126 is designed to address the toxicity and efficacy issues related to the MOA of existing approved CTLA-4 immuno-oncology therapies and to expand the potential of CTLA-4 as a target for the treatment of cancer. ADG116 is designed to target a unique conserved epitope of CTLA-4. And ADG104, a monospecific antibody that targets PD-L1 and is in Phase Ib and Phase II clinical trials concurrently in China.
Información de Adagene Inc
Símbolo de cotizaciónADAG
Nombre de la empresaAdagene Inc
Fecha de salida a bolsaFeb 09, 2021
Director ejecutivoLuo (Peter)
Número de empleados138
Tipo de seguridadDepository Receipt
Fin del año fiscalFeb 09
Dirección4F, Building C14, No. 218, Xinghu Street
CiudadSUZHOU
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísChina
Código postal- -
Teléfono8651287773632
Sitio Webhttps://www.adagene.com/
Símbolo de cotizaciónADAG
Fecha de salida a bolsaFeb 09, 2021
Director ejecutivoLuo (Peter)
Ejecutivos de Adagene Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Peter (Peizhi) Luo, Ph.D.
Dr. Peter (Peizhi) Luo, Ph.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
1.60M
+11.48%
Dr. Fangyong (Felix) Du, Ph.D.
Dr. Fangyong (Felix) Du, Ph.D.
Chief Technology Officer
Chief Technology Officer
--
--
Dr. Xu Jc, M.D., Ph.D.
Dr. Xu Jc, M.D., Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Zhao Qinghai, Ph.D.
Mr. Zhao Qinghai, Ph.D.
Chief Manufacturing Officer
Chief Manufacturing Officer
--
--
Mr. Tam (Raymond) Man Kin
Mr. Tam (Raymond) Man Kin
Chief Financial Officer, Director
Chief Financial Officer, Director
--
--
Ms. Gu (Vicky) Chunfang
Ms. Gu (Vicky) Chunfang
Senior Director of Finance
Senior Director of Finance
--
--
Ms. Zhou Ling
Ms. Zhou Ling
Senior Director of Human Resources
Senior Director of Human Resources
--
--
Ms. Li Yan
Ms. Li Yan
Senior Vice President of Bioinformatics and Information Technology
Senior Vice President of Bioinformatics and Information Technology
--
--
Ms. She (Kristine) Xiaohong
Ms. She (Kristine) Xiaohong
Senior Vice President, Head of Clinical Operations
Senior Vice President, Head of Clinical Operations
--
--
Dr. Liu Guizhong, Ph.D.
Dr. Liu Guizhong, Ph.D.
Head of Biology and Pharmacology
Head of Biology and Pharmacology
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Peter (Peizhi) Luo, Ph.D.
Dr. Peter (Peizhi) Luo, Ph.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
1.60M
+11.48%
Dr. Fangyong (Felix) Du, Ph.D.
Dr. Fangyong (Felix) Du, Ph.D.
Chief Technology Officer
Chief Technology Officer
--
--
Dr. Xu Jc, M.D., Ph.D.
Dr. Xu Jc, M.D., Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Zhao Qinghai, Ph.D.
Mr. Zhao Qinghai, Ph.D.
Chief Manufacturing Officer
Chief Manufacturing Officer
--
--
Mr. Tam (Raymond) Man Kin
Mr. Tam (Raymond) Man Kin
Chief Financial Officer, Director
Chief Financial Officer, Director
--
--
Ms. Gu (Vicky) Chunfang
Ms. Gu (Vicky) Chunfang
Senior Director of Finance
Senior Director of Finance
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Adagene Inc?
Los cinco principales accionistas de Adagene Inc son: Dr. Peter (Peizhi) Luo, Ph.D.
¿Cuántas instituciones poseen acciones de Adagene Inc (ADAG)?
A fecha de 2026Q1, 38 instituciones poseen acciones de Adagene Inc, con un valor de mercado combinado de aproximadamente 13.55M, lo que representa el 20.51% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -2119805.00.